Skip to main content
The Permian isn't standing still. Neither should your strategy. Join us for breakfast!
General Interest
Refining & Processing
Drilling & Production
Exploration & Development
Pipelines & Transportation
Sections
General Interest
Refining & Processing
Drilling & Production
Exploration & Development
Pipelines & Transportation
LNG
Energy Transition
Industry Statistics
Members Only
Special
Webcasts
White Papers
Podcast
Magazine
Surveys
Research
Events
Submit an Article
Iran war
Contact
About Us
Magazine Subscription
Newsletter Subscription
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Affiliated Brands
OFFSHORE
ENERGYTECH
MICROGRID KNOWLEDGE
OGJ RESEARCH
Follow us on
http://www.facebook.com/ogjonline
https://www.linkedin.com/company/oil-&-gas-journal
http://twitter.com/ogjonline
Recent Quotes
View Full List
My Watchlist
Apellis Pharmaceuticals, Inc. - Common Stock
Century Communities, Inc. Common Stock
Cincinnati Financial
Corgi MU 2x Daily ETF
Defiance Daily Target 2X Long IREN ETF
Defiance Daily Target 2x Long OKLO ETF
Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 2X ETF
Eaton Vance California Municipal Bond Fund Common Shares of Beneficial Interest
Eaton Vance Enhance Equity Income Fund II Common Stock
Eaton Vance Municipal Bond Fund Common Shares of Beneficial Interest, $.01
Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified
FB Financial Corporation Common Stock
First Mid Bancshares, Inc. - Common Stock
Headwater Gold Inc
Hyatt Hotels Corporation Class A Common Stock
Leverage Shares 2x Long FIG Daily ETF
MongoDB, Inc. - Class A Common Stock
PriceSmart, Inc. - Common Stock
ProKidney Corp. - Class A Ordinary Shares
REX American Resources Corporation
Scage Future - American Depositary Shares
Select Medical Holdings Corporation Common Stock
Silver Spruce Res Inc
Stillwater Critical Mnrls
Stillwater Critical Mnrls
Strive, Inc. - 15.00% Series A Perpetual SATS Preferred Stock
Sun Communities, Inc. Common Stock
Sunworks, Inc. - Common Stock
T-REX 2X Long SNOW Daily Target ETF
Telesat Corporation - Class A Common Shares and Class B Variable Voting Shares
The Alkaline Water Company Inc. - Common Stock
Tradr 2X Long APP Daily ETF
Vanguard Russell 3000 ETF
Varex Imaging Corporation - Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Definium Therapeutics, Inc. - Common Shares
(NQ:
DFTX
)
34.19
+1.72 (+5.30%)
Delayed Quote
Updated: 10:05 AM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Definium Therapeutics, Inc. - Common Shares
< Previous
1
2
Next >
Definium Therapeutics to Participate at Upcoming Investor Conferences
Today 7:01 EST
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
October 29, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
October 26, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
October 13, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
September 28, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
September 14, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
September 14, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
September 13, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
September 10, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
September 08, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
August 31, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
August 26, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
August 17, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
August 12, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
August 06, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
August 05, 2026
Issued on behalf of Helus Pharma (Nasdaq: HELP)
From
USA News Group
Via
GlobeNewswire
Definium Therapeutics Announces New Employee Inducement Grants
August 03, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
July 20, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
July 16, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
July 14, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
July 06, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity
From
MarketNewsUpdates.com
Via
GlobeNewswire
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 25, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
June 23, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics, Inc. Announces Proposed Public Offering
June 22, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
June 22, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
June 21, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
June 15, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
